These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1388131)

  • 1. Chemosensitizing effect of an antiestrogen, toremifene, on ovarian cancer.
    Mäenpää J; Sipilä P; Kangas L; Karnani P; Grönroos M
    Gynecol Oncol; 1992 Sep; 46(3):292-7. PubMed ID: 1388131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
    Sharp SY; Rowlands MG; Jarman M; Kelland LR
    Br J Cancer; 1994 Sep; 70(3):409-14. PubMed ID: 8080723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial.
    Mäenpää JU; Heinonen E; Hinkka SM; Karnani P; Klemi PJ; Korpijaakko TA; Kuoppala TA; Laine AM; Lähde MA; Nuoranne EK
    Gynecol Oncol; 1995 Jun; 57(3):294-8. PubMed ID: 7774832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subrenal capsule assay in selection of chemotherapy after operation for recurrent ovarian cancer.
    Venesmaa P; Ylikorkala O
    Br J Cancer; 1991 Jan; 63(1):84-6. PubMed ID: 1899195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The in vitro combination-effect of toremifene with CAF (cyclophosphamide, adriamycin, 5-fluorouracil) on growth of various human mammary carcinomas].
    Kuroiwa S; Maruyama S; Okada M; Abe F
    Gan To Kagaku Ryoho; 1998 Aug; 25(10):1581-9. PubMed ID: 9725052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance of combination and single agent chemosensitivity prediction in ovarian carcinoma using the subrenal capsule xenograft assay (SRCA).
    Stratton JA; Rettenmaier MA; Kucera PR; Berman ML; DiSaia PJ
    Gynecol Oncol; 1988 Jul; 30(3):416-21. PubMed ID: 3391423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance.
    DeGregorio MW; Ford JM; Benz CC; Wiebe VJ
    J Clin Oncol; 1989 Sep; 7(9):1359-64. PubMed ID: 2527971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Circumvention of cisplatin resistant ovarian cancer cells by antiestrogens].
    Ishii K; Kita T; Kudo K; Hisano A; Hirata J; Imaizumi E; Tode T; Kikuchi Y; Nagata I
    Nihon Sanka Fujinka Gakkai Zasshi; 1995 Jan; 47(1):19-26. PubMed ID: 7844449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
    Mäenpää J; Kangas L; Grönroos M
    Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Toremifene sensitized the effect of adriamycin on human breast cancer cell lines].
    Nakagomi H; Furuya K; Hagiwara J; Nishio T; Watanabe K; Muto S; Takano K; Tada Y
    Gan To Kagaku Ryoho; 1998 Apr; 25 Suppl 3():454-8. PubMed ID: 9589052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive and synergistic effects of a novel antiestrogen, toremifene (Fc-1157a), and human interferons on estrogen responsive MCF-7 cells in vitro.
    Kangas L; Nieminen AL; Cantell K
    Med Biol; 1985; 63(4):187-90. PubMed ID: 2419713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse.
    Robinson SP; Jordan VC
    Cancer Res; 1989 Apr; 49(7):1758-62. PubMed ID: 2522347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive and synergistic antitumor effects with toremifene and interferons.
    Kangas L; Cantell K; Schellekens H
    J Steroid Biochem; 1990 Jun; 36(3):259-62. PubMed ID: 2142249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subrenal capsule assay as a predictor of clinical response of ovarian cancer to chemotherapy: Part II.
    Mäenpää J
    Obstet Gynecol; 1985 Nov; 66(5):714-8. PubMed ID: 3903584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide, adriamycin, 5-fluorouracil and high-dose toremifene for patients with advanced/recurrent breast cancer. The Japan Toremifene Cooperative Study Group.
    Tominaga T; Nomura Y; Uchino J; Hirata K; Kimura M; Yoshida M; Aoyama H; Kinoshita H; Koyama H; Monden Y; Takashima S; Ogawa M
    Jpn J Clin Oncol; 1998 Apr; 28(4):250-4. PubMed ID: 9657010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of combination toremifene and medroxyprogesterone acetate (MPA) in vitro and in vivo.
    Kangas L; Grönroos M
    J Steroid Biochem; 1990 Jun; 36(3):253-7. PubMed ID: 2142248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of breast cancer patient of CAF (cyclophosphamide, adriamycin, 5-fluorouracil) resistant lung metastasis with remarkable response to reverse drug-resistance by toremifene].
    Kusama M; Kaise H; Nakayama S; Ohta D; Aoki T; Koyanagi Y
    Gan To Kagaku Ryoho; 1999 Jul; 26(8):1171-5. PubMed ID: 10431584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of Adriamycin cytotoxicity in a multidrug resistant Chinese hamster ovary (CHO) subline, CHO-Adrr, by toremifene and its modulation by alpha 1 acid glycoprotein.
    Chatterjee M; Harris AL
    Eur J Cancer; 1990 Apr; 26(4):432-6. PubMed ID: 2141509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatin.
    Stratton JA; Kucera PR; Rettenmaier MA; Dobashi K; Micha JP; Braly PS; Berman ML; DiSaia PJ
    Gynecol Oncol; 1986 Nov; 25(3):302-10. PubMed ID: 3781341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy of ovarian cancer.
    Ozols RF; Young RC
    Semin Oncol; 1984 Sep; 11(3):251-63. PubMed ID: 6435250
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.